Generic placeholder image

Current Rheumatology Reviews

Author(s): Lidiya Khituova, Venera Khabizhanova, Abdugani Musayev*, Gulsim Akhmetova, Elmira Almukhambetova and Vildan Indershiyev

DOI: 10.2174/1573397118666220802141420

DownloadDownload PDF Flyer Cite As
Risk Factors of Cardiovascular Pathology in Patients with Gout

Page: [72 - 75] Pages: 4

  • * (Excluding Mailing and Handling)

Abstract

Objective: To determine the frequency and assess the risk of cardiovascular disease in patients suffering from gout.

Background: Gout is a sign of disturbed metabolism, which is associated with cardiovascular diseases (CVD). Soaring mortality is associated with a lot of risk factors and comorbid conditions, which have to be dealt with the help of scientists and practitioners.

Methods: The following retrospective study included 218 patients suffering from gout according to the criteria of S.L. Wallace. The risk of major coronary events was calculated via the SCORE scale.

Results: Arterial hypertension and BMI > 25 kg / m2 (90.8%) have prevailed among the respondents. Increased level of total cholesterol (TC) was detected in 63.8% cases, decreased level of highdensity lipoproteins - in 71.6%, and hypertriglyceridemia - in 60.5% relevantly. 175 patients (80.3%) had high cardiovascular risk (estimated more than 5%). 43 (19.7%) of them had a low and medium risk of developing fatal CVD (1-4%). The high share of patients suffering from gout was endangered with cardiovascular pathology.

Conclusion: The most frequently matched risk factors among patients suffering from gout are an increase in BMI> 25 kg/m2 (90.8%) and dyslipidemia.

Keywords: Gout risk factors, cardiovascular pathology, cardiovascular risk, rheumatology, hyperuricemia, cardiovascular dis-eases (CVD).

Graphical Abstract

[1]
Roddy E, Doherty M. Epidemiology of gout. Arthritis Res Ther 2010; 12(6): 223.
[http://dx.doi.org/10.1186/ar3199] [PMID: 21205285]
[2]
Nasser-Ghodsi N, Harrold LR. Overcoming adherence issues and other barriers to optimal care in gout. Curr Opin Rheumatol 2015; 27(2): 134-8.
[http://dx.doi.org/10.1097/BOR.0000000000000141] [PMID: 25633242]
[3]
Qaseem A, Harris RP, Forciea MA, et al. Management of acute and recurrent gout: a clinical practice guideline from the american college of physicians. Ann Intern Med 2017; 166(1): 58-68.
[http://dx.doi.org/10.7326/M16-0570] [PMID: 27802508]
[4]
Khanna PP, Gladue HS, Singh MK, et al. Treatment of acute gout: A systematic review. Semin Arthritis Rheum 2014; 44(1): 31-8.
[http://dx.doi.org/10.1016/j.semarthrit.2014.02.003] [PMID: 24650777]
[5]
Kuo CF, Grainge MJ, Mallen C, Zhang W, Doherty M. Rising burden of gout in the UK but continuing suboptimal management: A nationwide population study. Ann Rheum Dis 2015; 74(4): 661-7.
[http://dx.doi.org/10.1136/annrheumdis-2013-204463] [PMID: 24431399]
[6]
Abhishek A, Roddy E, Doherty M. Gout - a guide for the general and acute physicians. Clin Med (Lond) 2017; 17(1): 54-9.
[http://dx.doi.org/10.7861/clinmedicine.17-1-54] [PMID: 28148582]
[7]
Kaul S, Gupta M, Bandyopadhyay D, et al. Gout pharmacotherapy in cardiovascular diseases: A review of utility and outcomes. Am J Cardiovasc Drugs 2021; 21(5): 499-512.
[http://dx.doi.org/10.1007/s40256-020-00459-1] [PMID: 33369719]
[8]
Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis 2017; 76(1): 29-42.
[http://dx.doi.org/10.1136/annrheumdis-2016-209707] [PMID: 27457514]
[9]
Klionsky DJ, Abdelmohsen K, Abe A, Abedin MJ, Abeliovich H, Arozena A, et al. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy 2016; 12(1): 1-222.
[http://dx.doi.org/10.1080/15548627.2015.1100356]
[10]
Bychkov ОА, Kondratiuk VE, Bychkova NG, Morozova ZV, Bychkova SA, Tarasiuk AP. Role of immune system in development and progress of combined arterial hypertension and gout. Wiad Lek 2019; 72(7): 1295-9.
[http://dx.doi.org/10.36740/WLek201907112] [PMID: 31398158]
[11]
Puig JG, Martínez MA. Hyperuricemia, gout and the metabolic syndrome. Curr Opin Rheumatol 2008; 20(2): 187-91.
[http://dx.doi.org/10.1097/BOR.0b013e3282f4b1ed] [PMID: 18349749]
[12]
Riedel AA, Nelson M, Joseph-Ridge N, Wallace K, MacDonald P, Becker M. Compliance with allopurinol therapy among managed care enrollees with gout: A retrospective analysis of administrative claims. J Rheumatol 2004; 31(8): 1575-81.
[PMID: 15290738]
[13]
Yu W, Cheng JD. Uric acid and cardiovascular disease: An update from molecular mechanism to clinical perspective. Front Pharmacol 2020; 11: 582680.
[http://dx.doi.org/10.3389/fphar.2020.582680] [PMID: 33304270]
[14]
Krishnan E. Gout and the risk for incident heart failure and systolic dysfunction. BMJ Open 2012; 2(1): e000282.
[http://dx.doi.org/10.1136/bmjopen-2011-000282] [PMID: 22337813]
[15]
Perez-Ruiz F, Martínez-Indart L, Carmona L, Herrero-Beites AM, Pijoan JI, Krishnan E. Tophaceous gout and high level of hyperuricaemia are both associated with increased risk of mortality in patients with gout. Ann Rheum Dis 2014; 73(1): 177-82.
[http://dx.doi.org/10.1136/annrheumdis-2012-202421] [PMID: 23313809]